IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 381 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $506,000 | +9.8% | 11,104 | -1.3% | 0.00% | 0.0% |
| Q2 2023 | $461,000 | +12.7% | 11,249 | -1.9% | 0.00% | 0.0% |
| Q1 2023 | $409,000 | -2.9% | 11,469 | +2.7% | 0.00% | 0.0% |
| Q4 2022 | $421,000 | +7.1% | 11,166 | +26.0% | 0.00% | 0.0% |
| Q3 2022 | $393,000 | +12.6% | 8,865 | -6.6% | 0.00% | 0.0% |
| Q2 2022 | $349,000 | +3.9% | 9,488 | +4.1% | 0.00% | 0.0% |
| Q1 2022 | $336,000 | -59.3% | 9,112 | -66.4% | 0.00% | -50.0% |
| Q4 2021 | $826,000 | +147.3% | 27,138 | +175.3% | 0.00% | +100.0% |
| Q3 2021 | $334,000 | -8.7% | 9,857 | +6.0% | 0.00% | 0.0% |
| Q2 2021 | $366,000 | -14.1% | 9,303 | -2.3% | 0.00% | 0.0% |
| Q1 2021 | $426,000 | -50.1% | 9,519 | -36.9% | 0.00% | -75.0% |
| Q4 2020 | $854,000 | +51.4% | 15,082 | +26.1% | 0.00% | +33.3% |
| Q3 2020 | $564,000 | -19.8% | 11,962 | -0.6% | 0.00% | -25.0% |
| Q2 2020 | $703,000 | +23.3% | 12,038 | -1.1% | 0.00% | 0.0% |
| Q1 2020 | $570,000 | -20.5% | 12,178 | +2.4% | 0.00% | 0.0% |
| Q4 2019 | $717,000 | +0.3% | 11,889 | -1.0% | 0.00% | 0.0% |
| Q3 2019 | $715,000 | -9.4% | 12,006 | -1.6% | 0.00% | -20.0% |
| Q2 2019 | $789,000 | +10.3% | 12,203 | +38.3% | 0.01% | 0.0% |
| Q1 2019 | $715,000 | -30.1% | 8,823 | -53.3% | 0.01% | -37.5% |
| Q4 2018 | $1,023,000 | +127.8% | 18,877 | +118.7% | 0.01% | +166.7% |
| Q3 2018 | $449,000 | +21.0% | 8,632 | -1.6% | 0.00% | 0.0% |
| Q2 2018 | $371,000 | -11.9% | 8,771 | -7.9% | 0.00% | -25.0% |
| Q1 2018 | $421,000 | -16.8% | 9,519 | -9.1% | 0.00% | 0.0% |
| Q4 2017 | $506,000 | -7.2% | 10,470 | -1.8% | 0.00% | -20.0% |
| Q3 2017 | $545,000 | +9.9% | 10,660 | +10.4% | 0.01% | +25.0% |
| Q2 2017 | $496,000 | +10.5% | 9,659 | -14.1% | 0.00% | 0.0% |
| Q1 2017 | $449,000 | +14.5% | 11,239 | +37.7% | 0.00% | 0.0% |
| Q4 2016 | $392,000 | -23.3% | 8,163 | -42.0% | 0.00% | -33.3% |
| Q3 2016 | $511,000 | -46.4% | 14,069 | -40.7% | 0.01% | +100.0% |
| Q1 2016 | $954,000 | -30.2% | 23,718 | +7.2% | 0.00% | -81.2% |
| Q4 2015 | $1,367,000 | – | 22,129 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |